Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

3-O-sulfated heparan sulfate translocation in altered membrane biology: A new strategy for early population screening and halting Alzheimer’s neurodegeneration

ArrestAD

ArrestAD proposes a novel and visionary thinking resulting from the demonstration of the central role of a particular heparan sulfate species at the intracellular level in neurons and in circulating cells in the molecular pathology of Alzheimer’s disease (AD). AD is a societal challenge for which there is neither prevention nor possible cure...
Funding Programme
Start Date
End Date
Total Funding
€ 3 991 096
European Countries Involved

A new brain-dedicated Positron Emission Tomography (PET) system to identify β-amyloid biomarker for the early diagnosis of Alzheimer’s disease and other causes of cognitive decline

CAREMIBRAIN

ONCOVISION is a Spanish SME specialised in design, development, production and commercialisation of organ-dedicated PET systems. Our company submits the present business innovation project with the overall objectives of (1) marketing an innovative brain-dedicated PET system to early diagnosis of Alzheimer’s disease (AD) and other causes of...
Funding Programme
Start Date
End Date
Total Funding
€ 4 393 596
European Countries Involved

A systems pharmacology approach to the discovery of novel therapeutics in Alzheimer´s disease

SYSPHARMAD

Alzheimer´s disease (AD) is the most common form of dementia, with over 35 million people suffering from it worldwide, and it constitutes a personal and societal tragedy of immense proportions. Fifty years of intense research have revealed many key elements of the biology of this neurodegenerative disorder. However, our understanding of the...
Funding Programme
Start Date
End Date
Total Funding
€ 1 296 000
European Countries Involved

A technology pLatform for the Assisted living of Dementia elDerly INdividuals and their carers

ALLADIN

The aim of the project is to utilise state-of-the-art in ICT in order to develop an integrated solution for the  self-management of dementia patients, and develop innovative tools to support this procedure. This  solution can be conceived as an integrated platform enabling distant monitoring of patient status and  facilitating personalised...
Funding Programme
Start Date
End Date
Total Funding
€ 1 980 757
European Countries Involved

Active Living For Alzheimer-patients -ALFA

ALPHA

By means of three different technologies, visual stimulation of mirror neurons in Alzheimer patients, an interactive agenda or diary and a movement monitoring system, people with dementia will be able to improve or sustain their cognitive functions. By developing, integrating and testing these technologies in home-care and residential settings we...
Funding Programme
Start Date
End Date
Total Funding
€ 2 162 987
European Countries Involved

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy

AETIONOMY

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and  (II) the focused application of this pipeline to derive clinically...

Funding Programme
Start Date
End Date
Total Funding
€ 17 546 060

affecTive basEd iNtegrateD carE for betteR Quality of Life

TeNDER

With an increasingly growing population in Europe, cognitive impairments as well as heart diseases are a major social and health issue. 1.2 million people in Europe are affected by Parkinson's disease (PD) while Alzheimer’s disease remains one of the biggest global public health challenges our generation is facing, while Cardiovascular disease...
Funding Programme
Start Date
End Date
Total Funding
€ 5 698 333
European Countries Involved

ALzheimer COoperative Valuation in Europe

The JA will be contribute to public health programmes in Europe and develop Alzheimers disease (AD) and dementia prevention and care models in different European countries. The aim is to contribute to improvements in health by supporting and facilitating quality and efficiency of public health and healthcare policies and interventions. Synergy and...
Funding Programme
Start Date
End Date
Total Funding
€ 613 100

Alzheimer's disease apolipoprotein pathology for treatment elucidation and development

ADAPTED

Alzheimer’s disease (AD) affects over 35 million people worldwide and yet there are currently no medicines which slow down the progress of the disease. The ADAPTED project aims to boost the development of new medicines by investigating an area of AD research which has previously received little attention – the APOE gene. The APOE gene is a well...
Funding Programme
Start Date
End Date
Total Funding
€ 6 796 740
European Countries Involved

Alzheimer’s Disease Diagnosis by Spectroscopy. Accurate and Non-Invasive Medical Device for the Diagnosis of Early Stage Alzheimer's Disease.

ADiRaS

Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s...
Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Amyloid imaging to Prevent Alzheimer’s Disease

AMYPAD

Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive...

Funding Programme
Start Date
End Date
Total Funding
€ 27 329 288
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).